Biomarker Predicts Breast Cancer Risk in Asymptomatic Women
|
By LabMedica International staff writers Posted on 18 Apr 2016 |
|
In healthy breast tissue, the percentage of cells expressing molecular marker Ki67 (green) and p27 (red) was low (Photo courtesy of Sung Jin Huh, Harvard Medical School).
A biomarker has been identified that may allow clinicians to predict the risk of an asymptomatic woman eventually developing breast cancer.
To identify this disease indicator, investigators at Harvard Medical School studied the association between breast cancer risk and the frequency of mammary epithelial cells expressing the proteins p27 (Cyclin-dependent kinase inhibitor 1B), estrogen receptor (ER), and Ki67 (Marker of proliferation Ki-67) in normal breast tissue from 302 women (69 breast cancer cases, 233 controls) who had been initially diagnosed with benign breast disease.
Immunofluorescence assays for p27, ER, and Ki67 were performed on tissue microarrays constructed from benign biopsies containing normal mammary epithelium and scored by computational image analysis.
Results revealed that the frequency of Ki67+ cells was positively associated with breast cancer risk among premenopausal women. Conversely, the frequency of ER+ or p27+ cells was inversely, but not significantly, associated with subsequent breast cancer risk. Notably, high Ki67+/low p27+ and high Ki67+/low ER+ cell frequencies were significantly associated with a five-fold higher risk of breast cancer compared with low Ki67+/low p27+ and low Ki67+/low ER+ cell frequencies, respectively, among premenopausal women.
This data suggests that the fraction of actively cycling cells in normal breast tissue may represent a marker for breast cancer risk assessment, which may therefore impact the frequency of screening procedures in at-risk women.
"Currently, we are not able to do a very good job at distinguishing women at high and low risk of breast cancer," said senior author Dr. Rulla Tamimi, associate professor of epidemiology at Harvard Medical School. "By identifying women at high risk of breast cancer, we can better develop individualized screening and also target risk reducing strategies."
The study was published in the April 1, 2016, issue of the journal Cancer Research.
Related Links:
Harvard Medical School
To identify this disease indicator, investigators at Harvard Medical School studied the association between breast cancer risk and the frequency of mammary epithelial cells expressing the proteins p27 (Cyclin-dependent kinase inhibitor 1B), estrogen receptor (ER), and Ki67 (Marker of proliferation Ki-67) in normal breast tissue from 302 women (69 breast cancer cases, 233 controls) who had been initially diagnosed with benign breast disease.
Immunofluorescence assays for p27, ER, and Ki67 were performed on tissue microarrays constructed from benign biopsies containing normal mammary epithelium and scored by computational image analysis.
Results revealed that the frequency of Ki67+ cells was positively associated with breast cancer risk among premenopausal women. Conversely, the frequency of ER+ or p27+ cells was inversely, but not significantly, associated with subsequent breast cancer risk. Notably, high Ki67+/low p27+ and high Ki67+/low ER+ cell frequencies were significantly associated with a five-fold higher risk of breast cancer compared with low Ki67+/low p27+ and low Ki67+/low ER+ cell frequencies, respectively, among premenopausal women.
This data suggests that the fraction of actively cycling cells in normal breast tissue may represent a marker for breast cancer risk assessment, which may therefore impact the frequency of screening procedures in at-risk women.
"Currently, we are not able to do a very good job at distinguishing women at high and low risk of breast cancer," said senior author Dr. Rulla Tamimi, associate professor of epidemiology at Harvard Medical School. "By identifying women at high risk of breast cancer, we can better develop individualized screening and also target risk reducing strategies."
The study was published in the April 1, 2016, issue of the journal Cancer Research.
Related Links:
Harvard Medical School
Gold Member
Automatic Hematology Analyzer
CF9600
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Manual Pipetting Aid
Pipette Controllers macro
Latest Pathology News
- Uncertainty-Aware AI Tool Improves Digital Pathology for Cancer Subtyping
- Study Highlights Biomarker Testing Delays in Lung Cancer Care
- Stain-Free Imaging Platform Matches Standard Cancer Pathology
- New Companion Diagnostic Expands Precision Medicine in Prostate Cancer
- Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer
- AI Tool Speeds Brain Tumor Classification from Routine Histology Slides
- IHC Companion Diagnostic Standardizes Mismatch Repair Testing for Cancer Immunotherapy
- AI Pathology Tool Predicts Meningioma Recurrence from Routine Slides
- 3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
- Blood-Based Method Tracks Gene Activity in the Living Brain
- FDA Approval Expands Automated PD-L1 Testing Across Solid Tumors
- AI-Powered Atlas Maps Immune Structures Linked to Cancer Outcomes
- AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy
- Rapid AI Tool Predicts Cancer Spatial Gene Expression from Pathology Images
- AI Pathology Test Receives FDA Breakthrough for Bladder Cancer Risk Stratification
- FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
Channels
Clinical Chemistry
view channel
FDA-Approved Test Identifies Low Risk of Large Esophageal Varices in Cirrhosis
Chronic liver disease contributes substantially to mortality, and clinicians routinely screen adults with compensated cirrhosis for varices to prevent bleeding. However, endoscopy is invasive and reso... Read more
Blood Protein Signature Diagnoses Pediatric IBD and Distinguishes Subtypes
Confirming pediatric inflammatory bowel disease (IBD) often requires imaging, endoscopy, and histopathology, prolonging time to diagnosis. Reliable, noninvasive blood tests remain an unmet need in routine... Read more
Molecular Diagnostics
view channel
Ultrasensitive ctDNA Assay Detects MRD in Breast, Colorectal, Renal Cancers
Minimal residual disease testing is increasingly used to guide adjuvant therapy and surveillance in solid tumors, but detecting very low levels of circulating tumor DNA remains challenging in routine practice.... Read more
Female-Specific RNA Biomarker May Help Explain Sex Differences in Immune Disease
Women show distinct susceptibility to infectious diseases and higher rates of autoimmune disorders, yet the molecular drivers remain unclear. This gap has limited sex-specific diagnostic and prognostic tools.... Read more
Hematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read more
Immunology
view channel
New Cellular Biomarkers Correlate with Disease Severity in Sjögren Disease
Autoimmune disorders arise when immune responses target self-antigens, driving chronic inflammation and long-term morbidity. In primary Sjögren disease, inflammation of salivary and lacrimal glands leads... Read more
Airway Immune Signature May Predict Tuberculosis Progression Risk
Tuberculosis remains difficult to predict and prevent, despite widespread exposure worldwide. An estimated quarter of the global population has been infected with Mycobacterium tuberculosis, yet only a... Read more
Microbiology
view channel
Machine Learning Reveals Consistent Gut Microbiome Patterns in Colorectal Cancer
Colorectal cancer has been repeatedly linked to alterations in the gut microbiome, yet findings have often varied across small, heterogeneous studies. Reproducibility has been limited by differing sequencing... Read more
Study Reveals Widespread Community Spread of Drug-Resistant Klebsiella
Multidrug-resistant Klebsiella pneumoniae is an escalating community health concern, driving recurrent urinary tract infections in older adults and complicating first-line antibiotic therapy.... Read more
Stronger Laboratory Services Support Timely Melioidosis Diagnosis Amid Global Spread
Melioidosis, a potentially fatal infection caused by Burkholderia pseudomallei, remains difficult to recognize because its symptoms can mimic tuberculosis and other illnesses. The disease is considered... Read more
Extracellular Vesicle Biomarker May Enable Noninvasive Monitoring of H. pylori
Helicobacter pylori infects an estimated 43.9% of the global population, affecting approximately 4.4 billion people worldwide. In many regions, including Africa, Eastern Europe, and Southeast Asia, prevalence... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read more
Industry
view channel
Project Aims to Develop First Single-Cell Assay for ADC Therapies
Antibody-drug conjugates are expanding rapidly in oncology, intensifying the need for biomarker strategies that capture tumor heterogeneity at cellular resolution. Single-cell profiling can delineate cellular... Read more
